Williams Cancer Institute

02/24/2026

In this episode, we explore the challenges of developing cancer treatments, the low success rates of clinical trials, and whether the pharmaceutical industry is broken or simply high-risk. Dr. Williams and Dr. Goodyear discuss the power of combining existing therapies, the role of the immune system, and how AI could shape the future of cancer research and treatment.

In this episode, we explore the real risks behind developing cancer treatments and the low success rates of clinical trials. Is the pharmaceutical industry a...

02/23/2026

Meet Dr. Jason R. Williams, founder of the Williams Cancer Institute and a pioneer in interventional oncology and intratumoral immunotherapy. Learn more about his innovative approach to cancer treatment and his professional journey here: https://williamscancerinstitute.com/about-us/

02/20/2026

In this episode, we explore the real risks behind developing cancer treatments and the low success rates of clinical trials. Is the pharmaceutical industry a broken system, or simply a high-risk, high-reward process?
Dr. Williams and Dr. Goodyear discuss how combining therapies already used in humans may help improve success potential, the important role of the immune system, and why collaboration is key to accelerating medical innovation.
We also dive into the future impact of artificial intelligence in medicine and how it could reshape cancer research and treatment.

In this episode, we explore the real risks behind developing cancer treatments and the low success rates of clinical trials. Is the pharmaceutical industry a...

02/20/2026

Drug repositioning explores how existing medications (aspirin, metformin, statins, PDE-5 inhibitors) may modulate the tumor microenvironment and improve immune response. Cancer is an ecosystem, not just rogue cells. Biology overlaps—but clinical validation is essential.

  For a long time, drug development followed an almost mechanical logic: one disease, one molecular target, one molecule designed […]

02/19/2026

Cancer isn’t only genetic. Chronic infections (H. pylori, HBV, HCV, EBV, HPV, parasites) can reprogram cells through epigenetic changes like abnormal DNA methylation. They create an “epigenetic field” that silently increases cancer risk—long before a tumor appears. Prevention matters.

  For a long time, cancer was explained almost exclusively as the result of genetic mutations—permanent errors in DNA that […]

02/18/2026

In cancer, the real battle happens in the tumor microenvironment. Tumors reprogram their metabolism—producing lactate and acidity that weaken immune cells. Understanding and targeting this hidden battlefield may help support more effective immunotherapy strategies.

  In American football, there is a well-known phrase: “Games are won and lost in the trenches.” This expression reminds […]

02/18/2026

Exploring new ways to personalize cancer care starts with understanding the process. At Williams Cancer Institute, medical approaches are evaluated on an individual basis, integrating diagnostic insights and clinical judgment to inform coordinated care strategies.
Learn more about how innovative, research-informed protocols may support personalized treatment discussions.*

02/17/2026

New research conversations are shaping how pancreatic cancer is being studied. In our upcoming video, we explore emerging scientific perspectives, the role of the immune system, and why timing and strategy may matter.
🎥 Coming soon on YouTube.

02/16/2026

Coming soon.
A thoughtful conversation exploring why cancer care cannot follow a one-size-fits-all model. The discussion examines patient variability, genetic differences, and how research and clinical experience are shaping more personalized, adaptive approaches to treatment—along with the regulatory and technological challenges involved.
🎥 Full video coming soon.
Stay tuned to learn more.

02/16/2026

Polyphenols and flavonoids—naturally found in fruits and plants—are being studied for their role in cancer research. These bioactive compounds may interact with pathways involved in oxidative stress, inflammation, and tumor biology. Ongoing research continues to explore their potential in integrative oncology.

  Cancer remains one of the leading causes of death worldwide and continues to represent a major challenge for modern […]

02/16/2026

Should medicine be delivered to the whole body—or to the tumor itself?

Most of the debate in oncology has focused on systemic delivery:
chemotherapy versus systemic immunotherapy.

But that framing misses a critical issue.

When medications are delivered systemically, only ~0.5–2% (often ~1%) actually reaches the tumor.
The rest is diluted, degraded, or diverted to healthy tissues—where toxicity accumulates.

And when tumor burden is large or multifocal, the challenge isn’t just reaching the tumor…
it’s penetrating the tumor microenvironment.

Systemic delivery comes with:
• Liver-first metabolism
• Non-tumor tissue exposure
• 98–99% of the associated toxicity

Intratumoral delivery changes the equation.

02/13/2026

🦠 Exploring the Gut–Immune Connection in Cancer Research

Could the microbiome influence how patients respond to immunotherapy? Learn how F***l Microbiota Transplantation (FMT) is being studied as part of emerging oncology research.

Read more here:
https://williamscancerinstitute.com/fecal-microbiota-transplantation-redefining-cancer-immunotherapy/